• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Boston Scientific touts data from Phase 3 study of selective internal radiation therapy

September 20, 2021 By Sean Whooley

Boston ScientificBoston Scientific (NYSE:BSX) today touted data from a Phase 3 clinical trial of its TheraSphere Y-90 glass microspheres treatment.

In the trial, the TheraSphere treatment successfully met both primary endpoints, including progression-free survival (PFS) and hepatic progression-free survival (hPFS) in patients with metastatic colorectal cancer (mCRC) of the liver.

Marlborough, Mass.-based Boston Scientific’s TheraSphere treatment, a selective internal radiation therapy (SIRT), consists of microscopic glass beads containing radioactive yttrium (Y-90) specifically delivered to target tumors. In the trial, TheraSphere was used as a second-line treatment in combination with standard of care systemic chemotherapy (SOC) for patients who had disease progression during or after first-line chemotherapy, according to a news release.

Findings from the EPOCH clinical trial were presented as late-breaking data at the European Society for Medical Oncology (ESMO) Congress 2021 and will be published in the Journal of Clinical Oncology.

The global, prospective trial randomized 428 patients with mCRC to second-line chemotherapy with or without the addition of the TheraSphere treatment. Both primary endpoints were met, with the addition of TheraSphere in treatment significantly increasing both PFS and hPFS.

Patients who received TheraSphere treatment with second-line chemotherapy were 31% less likely to show disease progression or death and 41% less likely to show hepatic disease progression or death when compared to receiving chemotherapy alone.

“EPOCH is the first positive phase 3 SIRT trial in any disease setting and the data is expected to support our regulatory submission to the U.S. FDA, with the hope that more patients with liver dominant mCRC will gain access to TheraSphere as a treatment option in the future,” Boston Scientific president of interventional oncology, peripheral interventions Peter Pattison said in the release.

TheraSphere holds FDA approval for treating unresectable hepatocellular carcinoma (HCC) and breakthrough device designation for expedited review as a treatment for patients with glioblastoma. Currently, use of TheraSphere for treating mCRC in the U.S. is investigational only. Safety and effectiveness have not yet been established for the treatment.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Immunotherapy, Oncology Tagged With: Boston Scientific

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS